The Daughter’s Return
By The Economist,
The Economist
| 12. 31. 2011
A glimmer of hope in the sad tale of sex-selective abortion in India
THE march of sex-selective abortion in Asia seems relentless. Not every society adopts the practice, but those that do—and they include the two largest countries on earth—have seen it spread through every social group, unhampered by growing wealth. Indeed, middle-income couples seem more willing and better able to manipulate the sex of their children than are the poor. And they are more likely to want smaller families, increasing the premium on sons in countries where males are seen as more valuable.
As a result, richer areas have more sex selection than poorer ones and sex selection tends to rise as countries get richer. In China the sex ratio at birth is much more distorted in rich Shanghai and Guangzhou than in poor Tibet. From 2001-11, India’s GDP more than doubled and the census of 2011 found only 914 girls aged 0-6 for every 1,000 boys, worse even than the abysmal tally in 2001, when there were 927 girls per 1,000 boys. (India counts the sex ratio differently...
Related Articles
By Timnit Gebru and Émile P. Torres, First Monday | 04.14.2024
The stated goal of many organizations in the field of artificial intelligence (AI) is to develop artificial general intelligence (AGI), an imagined system with more intelligence than anything we have ever seen. Without seriously questioning whether such a system can...
By Harold Brubaker, The Philadelphia Inquirer | 04.04.2024
Acompany started by University of Pennsylvania scientist Jim Wilson has received FDA approval to test a form of gene editing in infants for the first time in the United States, the company said Thursday.
The Plymouth Meeting company, iECURE, is...
By Jason Kehe, Wired | 04.11.2024
God help the babies! Or, absent God, a fertility startup called Orchid. It offers prospective parents a fantastical choice: Have a regular baby or have an Orchid baby. A regular baby might grow up and get cancer. Or be born...
By Nick Paul Taylor, BioSpace | 03.14.2024
A U.K. watchdog balked at the cost-effectiveness of Vertex Pharmaceuticals’ CRISPR-based sickle cell disease therapy Thursday, recommending against funding the treatment unless uncertainties can be cleared up satisfactorily.
The U.K. became the first country to authorize Vertex’s Casgevy (exagamglogene...